66 results about "Immune therapy" patented technology

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD122 / CD132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and / or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122 / CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

Disclosed herein are methods of preventing or reducing the development of colorectal cancer in a subject identified as at risk of colorectal tumorigenesis. The methods include administering to the subject a composition comprising a zwitterionic capsular polysaccharide derived from a Bacteroides uniformis bacteria in an amount effective to prevent or reduce the development of colorectal cancer. Methods of treating colorectal cancer, reducing tumor size or tumor growth, inducing Natural Killer cell activity, and inducing Lag- 3 on Natural Killer cells are also provided.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

The invention relates to the technical field of biomedical engineering, and discloses a detection method for esophageal squamous carcinoma CTC enrichment and immunotherapy curative effect dynamic evaluation, and the method utilizes a micro-fluidic chip to carry out electrical impedance detection and physical preliminary screening on cells in a whole blood sample. And performing anti-reclosing time sequence verification on the screened interstitial circulating tumor cells, triggering transient flow resistance regulation and control when conditions are met, and opening a lateral shunt channel to reduce the flow velocity of a main flow channel. And meanwhile, the adaptive optical imaging unit is synchronously switched to a long integral time mode to collect a fluorescence image. And finally, the data calculation terminal calculates an immunotherapy curative effect evaluation index in combination with cell counting, an omission compensation item and PD-L1 expression intensity. Through synchronous linkage of the flow velocity and exposure, the problem of weak fluorescence signal detection under high-speed flow is solved, and the evaluation accuracy is improved.

The invention belongs to the technical field of immunotherapy of allergic diseases, and provides a method for identifying dominant B cell epitopes and T cell epitopes in wheat omega-5 prolamin. According to the identification method provided by the invention, an immunoinformatics tool, a proliferation test, a degranulation test and the like are comprehensively applied, and the cell proliferation capacity, cell factor release, IgG / IgE binding capacity and degranulation capacity of T / B cell epitopes are evaluated. Results show that the T cell epitopes T1 and T2 sharing the same sequence are relatively strong in multiplication capacity, can up-regulate Th2 related cell factors, but do not have degranulation activity. Three B cell peptide fragments B3, B4 and B9 which share a common motif region QQXPQQQ (X = F, L) can promote IgG / IgE binding and degranulation capabilities. These findings would contribute to the development of epitope-based immunotherapies against wheat allergy individuals.

This invention relates to compositions comprising an immunogen and a manganese glycerophosphate (MnGp) gel useful in raising an immune response in a subject, vaccinating a subject, and / or immunotherapy, such as cancer immunotherapy, in a subject. In addition, this invention relates to MnGp gels and methods of synthesizing the same using mechanical shear stress and / or synthesis of nanoparticles.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

This disclosure contemplates methods of detecting, measuring, and / or quantifying a tensional force on cells that express an antigen. In certain embodiments, this disclosure relates to methods and devices disclosed herein used to determine or monitor whether a cancer therapy or other immunotherapy is appropriate for a specific patient. In certain embodiments, the therapy is administering blinatumomab or other bispecific engager to a patient.

The present disclosure relates to methods and systems for predicting a subject's responsiveness to treatment or therapy. Specifically, the methods and systems provided herein may predict whether a subject suffering from disease or cancer may respond to immune therapy, including treatment with an immune checkpoint inhibitor such as agonist anti-CD137 antibodies, PD-1 antagonists, anti-CTL4 antibodies, or any combination thereof.

The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. It was found that responders of immunotherapeutic treatments have a higher amount of B-cell exosomes in their blood than non-responders. Aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after B-cell exosomes have been detected in a biological sample from the subject.

Compounds for the prevention and treatment of cancer have a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist operatively linked to an antibody peptide operatively linked to a second binding peptide from an endostatin or plasminogen derived peptide sequence.

The invention discloses an engineering fibroblast as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the engineering fibroblast provided by the invention, a proinflammatory factor IL-1 is neutralized by secreting IL-1RA, an inflammatory loop mediated by the proinflammatory factor IL-1 is broken, and a tumor immune microenvironment is remodeled, so that inhibition on immune effector cells (such as T cells and NK cells) is indirectly and effectively relieved, and favorable conditions are created for other immunotherapy methods or body autoimmune clearance; the problem that the immunosuppressive tumor microenvironment cannot be regulated and controlled well is solved. Meanwhile, the defects that the half-life period of the recombinant IL-1RA protein is short, frequent administration is needed, the local drug concentration of the focus is difficult to maintain and the like are overcome, stable and high-concentration delivery of the therapeutic protein is realized, and the pharmacokinetic bottleneck of the traditional protein drug is overcome.

Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.

The present invention pertains to the use of small molecules in the treatment of cancer. These compounds, which are small-molecule Furin inhibitors, show an ability to enhance sensitivity to immunotherapy and radiotherapy treatments, leading to tumor regression in mice and improved overall survival. Treatment of cancer cells with these compounds resulted in the elimination of the capacity for tumor cells and organoids to grow and invade. These results demonstrate the interest of using these small-molecule Furin inhibitors as therapeutic interventions for cancer patients.

Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that targets the cell-surface protein(s).

The application discloses a nanoscale coordination polymer NP@DoxCu based on copper ions and doxorubicin as well as a preparation method and application thereof, and relates to the technical field of ovarian cancer treatment. 2+ The nanoscale coordination polymer NP@DoxCu uses a ROS-sensitive polymer PSSP, doxorubicin Dox and Cu 2+ The application constructs a ROS-sensitive copper apoptosis nanoplatform NP@DoxCu. 2+ The platform is rapidly decomposed under the action of intracellular reductase and in a low-pH environment after entering cells; Cu 2+ cooperates with doxorubicin to not only directly kill cancer cells but also induce immune cell death; in addition, the NP@DoxCu remodels the tumor immune microenvironment, reorients tumor-associated macrophages (TAMs) and regulates T cells, thereby realizing effective immunotherapy in vivo; the combination of the copper apoptosis and the immunotherapy provides a new strategy for the treatment of ovarian cancer.

The present disclosure relates, inter alia, to methods for the prevention and / or reduction of immune checkpoint inhibitor-mediated gastrointestinal side effects by administering therapeutic intestinal alkaline phosphatases. The present disclosure further relates to compositions comprising the combination of immune-checkpoint immunotherapies with therapeutic alkaline phosphatases and use of the compositions in the prevention and / or treatment of immune checkpoint inhibitor-mediated gastrointestinal side effects, such as colitis.

This invention provides a method for treating subjects with cancer. [Solution] A method comprising the step of administering TUSC2 therapy, which is one of the tumor suppressor therapies, wherein the subject has been treated with or is currently being treated with at least one immune checkpoint inhibitor. Preferably, the method wherein at least one immune checkpoint inhibitor comprises an anti-PD1 agent.

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

The present invention relates to a method of predicting a response of a patient suffering from cancer. Further, the prevent invention relates to a method of providing a survival prognosis to a patient suffering from cancer. Furthermore, the present invention relates to a method of determining whether to treat a patient suffering from cancer. In addition, the present invention relates to a method of selecting a patient suffering from cancer to benefit from immunochemotherapy or immunotherapy. Moreover, the present invention relates to a kit for carrying out these methods.

This invention discloses a set of biomarkers, scoring models, and applications for assessing immunotherapy response and / or prognosis in head and neck squamous cell carcinoma, relating to the field of biomedical technology. The biomarkers include ITGB1, FTH1, SPP1, CD3D, CXCL9, and IL2RB. The STRIDE score is obtained by calculating the geometric mean ratio of the expression levels of the aforementioned six biomarkers, which can be used to assess the likelihood of high or low response to immunotherapy and / or prognostic risk in subjects. This invention constructs a spatial domain scoring model based on the D4 and D5 / D6 spatial domains to obtain the STRIDE score, reflecting the patient's spatial immune status, thereby enabling the assessment of prognostic risk and the suitability of immunotherapy for patients with head and neck squamous cell carcinoma.